The Second Circuit Court of Appeals has affirmed a lower court's decision regarding the Connecticut Drug Price Cap (DPC), which affects pharmaceutical distributors. The ruling, issued on October 20, 2026, denies the Healthcare Distribution Alliance's (HDA) request for a preliminary injunction against the enforcement of the DPC. This decision has significant implications for how drug prices are regulated in Connecticut and could influence similar laws in other states.
The HDA, a national trade association representing pharmaceutical wholesale distributors, argued that the DPC violates the dormant Commerce Clause of the U.S. Constitution. This clause prevents states from enacting laws that discriminate against or excessively burden interstate commerce. The HDA claimed that the DPC unfairly targets out-of-state distributors and imposes penalties on those who do not comply with its pricing regulations.
The case stems from a December 24, 2025, order by the U.S. District Court for the District of Connecticut, which denied HDA's motion for a preliminary injunction. The HDA appealed this decision, claiming that the lower court had abused its discretion in determining that the association had not shown a likelihood of success on the merits of its claims.
The DPC, enacted as part of Connecticut Public Act No. 25-168, seeks to cap prices for off-patent branded drugs, generic drugs, and interchangeable biologic products sold in the state. The law applies to all wholesale distributors, regardless of their location, and imposes civil penalties for those who fail to comply. HDA contends that the DPC discriminates against out-of-state businesses and constitutes an impermissible extraterritorial regulation.
In its ruling, the Second Circuit concluded that the District Court did not abuse its discretion. The court found that the DPC treats all covered distributors equally, regardless of their state of origin. The judges noted, "The [Drug Price Cap] treats all covered distributors the same," and therefore does not discriminate against out-of-state entities.
Furthermore, the court addressed HDA's claim that the DPC has extraterritorial effects. The judges ruled that a state law must have a specific impermissible effect to violate the dormant Commerce Clause. The court stated, "A state statute violates the dormant Commerce Clause if it ... has the practical effect of extraterritorial control of commerce occurring entirely outside the boundaries of the state in question." The judges found that the DPC applies solely to drug sales within Connecticut and does not directly regulate transactions that occur outside the state.
The impact of this ruling is significant for the pharmaceutical industry, particularly for distributors who sell drugs in Connecticut. By upholding the DPC, the Second Circuit has allowed Connecticut to enforce its pricing regulations, which could lead to similar laws being enacted in other states. The ruling may also encourage states to pursue measures aimed at controlling drug prices, especially in light of rising healthcare costs.
Legal experts suggest that this decision may set a precedent for how states can regulate drug pricing without violating the dormant Commerce Clause. The ruling clarifies that as long as state laws treat all distributors equally and do not impose undue burdens on interstate commerce, they are likely to withstand legal challenges.
Looking ahead, it remains to be seen whether the HDA will pursue further legal action, including a potential appeal to the U.S. Supreme Court. The court filing did not indicate whether the HDA plans to challenge the ruling further. However, the implications of this case could resonate beyond Connecticut, as other states consider similar drug price regulations.